SimPath licenses novel ORNL system for enhanced synthetic biology
SimPath has licensed a novel cloning system developed by the Department of Energy's Oak Ridge National Laboratory that generates and assembles the biological building blocks necessary to synthetically bioengineer new medicines and fuels.
Michelle Buchanan, deputy for science and technology at Oak Ridge National Laboratory, and Robert Moseley and Ben Mohr of SimPath signed an agreement for SimPath to license a novel ORNL cloning system that assembles the biological building blocks necessary to synthetically bioengineer new medicines and fuels.
Jason Richards/Oak Ridge National Laboratory, US Department of Energy
Oak Ridge National Laboratory scientists have developed a novel technology for enhanced synthetic biology, which has been licensed by Knoxville, Tenn.-based startup SimPath. ORNL co-inventor Xiaohan Yang, Robert Moseley and Ben Mohr of SimPath and ORNL co-inventor Jerry Tuskan will continue to partner on the cloning tool.
Genevieve Martin/Oak Ridge National Laboratory, US Deptartment of Energy
Knoxville, Tennessee-based startup SimPath will further develop ORNL's cloning method into a multi-gene DNA assembly kit and software package for customers who use synthetic biology techniques. Synthetic biology leverages genome sequences of organisms, such as bacteria, yeast and plants, and reassembles the DNA parts to manufacture products that are difficult to obtain naturally.
ORNL researchers developed the cloning system to aid studies of drought-resistant plants that rely on a water-saving form of photosynthesis known as crassulacean acid metabolism, or CAM. The new system has been beta-tested at the DOE Joint Genome Institute, where it enabled a 50 percent increase in production.
The method offers flexible cloning with fewer biodesign restrictions and can be automated so that multiple genes can be connected seamlessly in a chain, creating better compatibility when connecting various protein-coding DNA parts.
"The system has also been engineered to shuttle between different biological systems," said Jerry Tuskan, co-inventor and chief executive officer of the Center for Bioenergy Innovation led by ORNL. "The easily transferable platform can be used to assemble the gene constructs from a large collection of DNA fragments ready to be transformed in a variety of hosts including bacteria, yeast, plant and mammalian cells."
"Our researchers are delivering innovative breakthroughs in synthetic biology to enable the next generation of bioengineered material goods," said Moe Khaleel, associate lab director for Energy and Environmental Sciences at ORNL. "We value our industrial partners like SimPath who bridge scientific discovery with technology innovationto accelerate the path to commercialization."
SimPath plans to provide an accessible product that helps synthetic biology researchers reduce operating costs, increase efficiency and more quickly commercialize products.
"In the fast-paced world of synthetic biology, our goal is to accelerate our customers' design-build-test cycles," said Robert Moseley, president and co-founder of SimPath. "By providing them flexible DNA assembly tools, we can further enable the plant synthetic biology community to introduce new products to the market faster."
ORNL and SimPath will continue to partner on the cloning tool, using feedback from SimPath's customers to enhance the system and fine-tune characteristics such as shelf-life, which determines the viability of live products.
Other news from the department business & finance
